Grant R. Zimmermann

Managing Director of Business Development, Blavatnik Biomedical Accelerator

Displaying: 31 - 40 of 68 Results

Invention

The next generation of cholesterol screening - A personalized diagnostic index for the improved assessment of cardiovascular risk using a novel method for the measurement of lipoprotein subtypes

OpportunityThis program offers the next generation of cholesterol screening. In 2013, 96 million visits to doctors' offices in the US included a cholesterol test.Problem/Unmet needCurrent practice of measuring total HDL level in serum does not…

Investigators

  • Frank Sacks

Invention

Mass spectrometry-based in vitro kinome activity assay

This technology is a new generation, high-throughput assay to quantitatively assess the activity of the kinome in a variety of samples. Cocktails of synthetic peptides are combined with a sample of interest and phosphorylated by kinases in the…

Investigators

  • Steven P. Gygi
  • Judit Villen
  • Kazuishi Kubota
  • Yong Yu

Invention

Protein-based therapies using quantitatively designed proteins

A bipartite, quantitatively designed protein having two discrete ligands and a linker; one ligand having the ability to strongly bind to a particular cell, the other having the ability to affect a target only when the previous ligand binds. For many…

Investigators

  • Pamela A. Silver
  • Pablo Cironi
  • David G. Miguez

Invention

Gluconeogenesis as a pro-survival treatment for neurons under stress

A series of AAV-based gene therapy approaches to reprogram certain metabolic enzymes in rod and cone cells in the eye to promote survival in degenerative conditions such as retinitis pigmentosa. Additionally, an independent series of such vectors…

Investigators

  • Constance L. Cepko
  • Claudio Punzo

Invention

Knockout mouse model for human liver cancer

While most hepatocytes in healthy liver are resting cells, deletion of Mad2 in liver activates the cell cycles and causes proliferation of hepatocytes. Cre-mediated, simultaneous liver-specific knockout of Mad2 and p53 induces mouse cancer which…

Investigators

  • Peter K. Sorger
  • Ying Yue

Invention

A fusion intermediate state of HIV-1 gp41, targeted by broadly neutralizing antibodies, for purposes of vaccination

HIV infection generally induces a strong antibody response to the envelope glycoprotein, the sole antigen on the virion surface. Most of the induced antibodies are ineffective in preventing infection, however, as they are either non-neutralizing or…

Investigators

  • Stephen C. Harrison
  • Gary H. Frey
  • Bing Chen

Invention

Metabolic labeling and direct imaging of choline-containing phospholipids in vivo

A functional analog of a metabolic phospholipid precursor has been devised that, when contacted with cells, becomes incorporated into a cells endogenous phospholipids through cellular metabolic processes. The resulting phospholipids contain a moiety…

Investigators

  • Adrian Salic

Investigators

  • Christopher JL Murray
  • Yidong Ding
  • Caroline Cook Alter
  • Prasanta Mahapatra

Invention

Migration inhibitory factor (MIF) knockout mouse

To study the biological role of migration inhibitory factor (MIF), a pleiotropic cytokine, we generated a mouse strain lacking MIF by gene targeting in embryonic stem cells. Analysis of the role of MIF during sepsis showed that MIF-/- mice were…

Investigators

  • John R. David
  • Marcelo Torres Bozza
  • Craig Gerard

Invention

Inhibitors of protein-processivity factor

Harvard investigators have discovered that Pol interacts with a processivity factor at a site that is distinct from sites of normal interaction between known Pol family members and other cellular factors. Unlike most protein-protein interactions,…

Investigators

  • Donald M. Coen
  • James M. Hogle
  • Harmon Zuccola
  • Kristie Grove Bridges
  • Carl Elkin
  • Scott R. Lokey

Page 4 of 7